News

Please be aware of suspicious e-mails purporting to be from our company's employees and directors

Please be aware of suspicious e-mails purporting to be from our company's employees and directors

On the occasion of our 125th anniversary, our corporate slogan and logo design have been renewed.

Lab & office opened at "Nakanoshima Qross (Future Medical International Center)"

ROHTO Pharmaceutical Launches an AI Project Using Microsoft AI Co-Innovation Lab

Strategic Business Partnership between ROHTO MediLuxe Europe and EMA AESTHETICS

ROHTO Pharmaceutical Co., Ltd. Investing to Develop Novel Solution for Urinary Incontinence Symptoms, Venturing into New Values, Products, and Businesses in the Healthcare Sector.

Goals for 2030 in non-financial areas (environment/society) "Sustainability Goals 2030"

Establishment of Sustainability Targets 2030 (environmental and social axis)

Fujita Academy and Rohto Pharmaceutical Co., Ltd. establish a joint venture and enter the real world data business.

Fujita Gakuen and ROHTO Pharmaceutical Co., Ltd. established a joint venture and entered the real-world data business.

Announcement: Commencement of Phase II Clinical Trials for Janus Kinase Inhibitor "ROH-201" in Japan

ROHTO Pharmaceutical's Mother Plant, Ueno Techno Center, Commences Operations of New Facility

Announcement Regarding the Acquisition of Full Ownership of Naris Cosmetics Vietnam Co., Ltd. by ROHTO Mentholatum (Vietnam) Co., Ltd.

Announcement of Joint Venture Establishment for Advancing Regenerative Medicine Business in China

Notice of Commencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202"

Participation in the Osaka Pavilion at the 2025 World Exposition in Japan (Osaka and Kansai Exposition)

Announcement of Collaborative Research Agreement for Creating a Solution to Predict Systemic Diseases from Eye Health Information

Completion of Share Acquisition of Amato Pharmaceutical Products, Ltd. by ROHTO

Announcement of Commencement of Domestic Phase III Clinical Trial for Cytomegalovirus Endotheliitis

Announcement: Commencement of Phase II Clinical Trials for Janus Kinase Inhibitor "ROH-201" in Japan

Notice of Commencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202"

Announcement of Collaborative Research Agreement for Creating a Solution to Predict Systemic Diseases from Eye Health Information

Announcement of Commencement of Domestic Phase III Clinical Trial for Cytomegalovirus Endotheliitis

We evaluated the performance of rapid test kits for coronavirus (SARS-CoV-2) antigens using laboratory samples.

Initiation of Phase II Clinical Trial for Regenerative Medical Products Using Allogeneic Mesenchymal Stem Cells for Severe COVID-19 Pneumonia Patients

Licensing Agreement with BioMimetics Sympathies for COVID-19 Treatment Candidate and Establishment of Research Organization 'RB⁺' to Uncover Novel Drug Targets from Regenerative Medicine Research

Announcement Regarding Acquisition of Olympus RMS Corporation's Stock (Transfer Agreement)

Announcement: Commencement of Domestic Phase II Clinical Trial of Janus Kinase Inhibitor "ROH-201"

Announcement of Licensing Agreement for Ophthalmic Treatment "DW-1001"

Establishment of ROHTO Advanced Research Hong Kong Limited as a Hub for Cutting-edge Research in Hong Kong